Wen Xiao

Wen Xiao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2024 in Cancer Letters
Verified
Journal Article
Closed access
WLWeiquan Li
Weiquan Li
JLJingchong Liu
Jingchong Liu
TYTiexi Yu
Tiexi Yu
FLFeiyi Lu
Feiyi Lu
QMQi Miao
Qi Miao
XZXiaoping Zhang
Xiaoping Zhang

5 November 2020 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
XWXue‐Gang Wang
Xue‐Gang Wang
YZYong‐Wu Zhu
Yong‐Wu Zhu
TWTao Wang
Tao Wang
BCBin Chen
Bin Chen
JXJinchun Xing
Jinchun Xing
WXWen Xiao
Wen Xiao
Inflammation status are especially for tumor growth, and microRNAs (miRNAs) confirmed to participate in cancer occurrence and progression. However, the role of miR‐483‐5p and the relation with inflammation have not been elucidated in renal cell cancer (RCC). In this study, we intended to explore miR‐483‐5p expression and the relationship of inflammation status in clear cell renal cell cancer (ccRCC). Using microarray and qRT‐PCR (Quantitative Real‐time Polymerase Chain Reaction), we investigated the miR‐483‐5p expression in plasma and ccRCC cancer tissues. Then, we analyzed the correlation of miR‐483‐5p with clinicopathological parameters and inflammation status in ccRCC. Receiver operator characteristic (ROC) curves analysis was used to analyze the discrimination efficiency of miR‐483‐5p. in vitro experiments explored the biological role of miR‐483‐5p in renal cancer cells. miR‐483‐5p expression was upregulated in plasma of 5 patients with microarray and 12 patients with qRT‐PCR in ccRCC at day 7 postoperatively. In addition, low expression of miR‐483‐5p was found in 58 ccRCC cancer tissues when compared with non‐cancerous tissues. miR‐483‐5p could sufficiently discriminate ccRCC with the area under the curve (AUC) of 0.739 (P < .0001) from normal tissues. Higher expression of miR‐483‐5p was positively related to lower tumor stage and higher relative expression of miR‐483‐5p was inversely related to neutrophil‐to‐lymphocyte ratio (NLR) (P = .03) and lymphocyte‐to‐monocyte ratio (LMR) (P = .026). Overexpression of miR‐483‐5p lead to reverse epithelial‐mesenchymal transition (EMT) process, restrain cell proliferation and metastasis of renal cancer cells. Our findings suggest that miR‐483‐5p expression is negatively correlation with inflammation status and may be a potential plasma biomarker for ccRCC.

14 September 2023 in MedComm – Oncology
Verified
Journal Article
Open access
WLWeiquan Li
Weiquan Li
XMXiangui Meng
Xiangui Meng
TYTiexi Yu
Tiexi Yu
XSXin Shi
Xin Shi
WDWei Dong
Wei Dong
WXWen Xiao
Wen Xiao
Lymphocyte Antigen 96 (LY96) was identified as an oncogene in several tumors. However, its role in renal cancer has not been explored. In the study, LY96 is identified abnormally expressed using several public kidney cancer sequencing data. The expression level of LY96 is validated using paired clinical samples. Survival analyses and ROC curves are used to examine its prognostic and diagnostic value. Gene sets enrichment analyses (GSEA) show LY96 might influence immune processes. Then immune infiltration analyses results suggest that LY96 is positively correlated with M2 macrophages infiltration in RCC. Single‐cell data are used to verify its association with macrophages. Moreover, LY96 is positively with various immune scores and might affect the efficacy of immunotherapy. Drug screening results show LY96 might be the target of vemurafenib and etoposide. Further experiments confirm the spatial co‐localization of LY96 and M2, and knocking down LY96 can inhibit M2 polarization. Cell viability experiments indicate that knocking down LY96 would result in a decrease in the resistance of M2 macrophages to etoposide. The study shows LY96 could act as an unfavorable biomarker for RCC and possibly contribute to cancer progression by promoting the infiltration of M2 macrophage. LY96 could be a novel therapeutic target for RCC.

20 January 2021 in Aging
Verified
Journal Article
Open access
WXWen Xiao
Wen Xiao
TWTao Wang
Tao Wang
YYYuzhong Ye
Yuzhong Ye
XWXuegang Wang
Xuegang Wang
BCBin Chen
Bin Chen
XZXiaoping Zhang
Xiaoping Zhang
Invasion and metastasis are the main causes of poor prognosis in patients with clear cell renal cell carcinoma (ccRCC). The homeodomain interacting protein kinases (HIPKs) can regulate cell proliferation and apoptosis. Little is known about the prognostic role of HIPKs in ccRCC. Here we use Kaplan-Meier survival analysis and multivariate analysis to analyze the correlation of overall survival (OS) and disease-free survival (DFS). ROC curves analyzed the relationship between clinicopathological parameters and HIPK3 expression in ccRCC. Univariate analysis and multivariate analysis confirmed that the expression of HIPK3 was associated with OS (HR, 0.701; P=0.041) and DFS (HR, 0.630; P=0.012). Low HIPK3 expression was a poor prognostic factor and HIPK3 expression was significantly down-regulated in ccRCC cancer tissues when compared with normal renal tissues. In vitro cell results also confirmed that HIPK3 over-expression could inhibit tumor growth and malignant characteristics. The results indicate that low expression of HIPK3 in ccRCC tissues is significantly associated with poor survival rates in tumor patients, and HIPK3 may be used as a valuable biomarker and inhibitor of ccRCC.

23 January 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XMXiangui Meng
Xiangui Meng
WLWeiquan Li
Weiquan Li
TYTiexi Yu
Tiexi Yu
FLFeiyi Lu
Feiyi Lu
CWCheng Wang
Cheng Wang
XZXiaoping Zhang
Xiaoping Zhang

20 February 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
XLXinwei Li
Xinwei Li
YZYuanpeng Zhang
Yuanpeng Zhang
YYYuzhong Ye
Yuzhong Ye
WXWen Xiao
Wen Xiao
LLLei Liu
Lei Liu
XZXiaoping Zhang
Xiaoping Zhang
Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%–30% of patients were diagnosed with metastatic RCC in the beginning, while the median overall survival (OS) of metastatic RCC systemic therapy ranges from 16 months to 50 months. Immunotherapy, a novel therapy that relies on the specific binding of immune cells and tumor cells, may be a potential therapy for advanced renal cell carcinoma. While chimeric antigen receptor NK-cell (CAR-NK) therapy has been investigated in a variety of solid tumors, specific research on its application to RCC has also been reported by several teams. In this review, we introduced the cytotoxicity mechanisms of NK cells, summarized the connections between RCC and NK cells, and posted new insights into renal cell carcinoma CAR-NK therapy. To date, most researches focusing on renal cell carcinoma and NK cells only claimed the mechanisms of NK cell cytotoxicity and NK cell immune suppression and even immune escape, yet the molecules involved could also be interesting targets for renal cell carcinoma CAR-NK therapy.